Icon

ZOSYN (nda050684)- (EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL,EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL,EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL,EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL)

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM WYETH PHARMS
EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL,EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL,EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL,EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL
Yes No
2023-Apr-14 Expired
None None
None No
ZOSYN is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of:  Intra-abdominal infections in adult and pediatric patients 2 months of age and older  Nosocomial pneumonia in adult and pediatric patients 2 months of age and older  Skin and skin structure infections in adults  Female pelvic infections in adults  Community-acquired pneumonia in adults.
19 0 18
Total Other Developers None
Drugs with Suitability Yes
EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL ** ** - - -
EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL ** ** - - -
EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL ** ** - - -
EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL ** ** - - -
NDA Sales Available Total Generic Sales Available
No 16
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ****** ******** ****** ************** **., ***. *********** ******* ****, ******, ******** ******, ***** (***) ***
****** ***** ****** ******* ***** *** ******* ******* *********** ** **: *** ** ***, *** ** ***, *** ** ***, *** ** ***, *****, ***, **** **: *-*/*, *-* & *-*, ********* *******, ********* ******, ************, ********* ******, ***** (***) ***
****** ***** ****** ******* ********* ****** ******* *********** ****-***, **.**.***, **********, ********** ******, *******-********** ********, *******, ********* ******, ***** (***) ***
****** ******** *** *** *** ******** ********** ******** ******** ********* *********** *** ********** *, *******, ****** *****, ***** (***) ***
****** ********* **** ***** ****** ****** *** *********** ****** ******* *** *** ***** ******, ** **,***, *.*** *******, ****** *****, ***** (***) ***
****** ********* **** ***** *.*.*. *********** *** **** ******** ********** **, *******, *****, ***** (***) ***
****** ******** ******** ***** ************** **., ***. *********** **. ***, ******* ****, ******* ****., *****, ******, ***** (***) ***
****** ********* *** ** ***** *.*.*. *********** *** **** ******** ********** **, *******, *****, ***** (***) ***
****** ****** ****** ********* ******* ******* *********** ***, *.*.*.*., *********, ********, ******* ******, ***** (***) ***
****** ************ ************ *********** ******* ******* *********** ******* ******* ********, *** ***, ***********, ************ ****, *********, ********* ******, ***** (***) ***
****** ************ ************ *********** ******* ******* *********** **** ****** ********, ***/* & ***/**, *************, ***********, ************ ****,, *********, ********* ******, ***** (***) ***
****** ******** *** *** *** ******** ********** ******** ******** ********* *********** *** ********** *, *******, ****** *****, ***** (***) ***
****** ****** ******** ***** ************** **., ***. *** *********** **. ***, ******* ****, ******* ****., *****, ******, ***** (***) ***
****** ********* **** ***** *.*.*. *********** *** **** ******** ********** **, *******, *****, ***** (***) ***
****** ********* *** ** ***** *.*.*. *********** *** **** ******** ********** **, *******, *****, ***** (***) ***
****** ******** ******** ***** ************** **., ***. *********** **. ***, ******* ****, ******* ****., *****, ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.